Abstract
This paper reports results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan. The study included 16312 patients examined in different cities during 2011-2012. It showed that ascoril expectorant (Glenmark) at a standard dose is an effective agent for the treatment of cough in children above 3 years and adults aged up to 78 years with ARVI and acute bronchitis, exacerbation of these conditions or grade I-II chronic obstructire pulmonary disease. Most patients reported good therapeutic effect within 1 day after intake. Ascoril expectorant caused no adverse reactions and was well tolerated by the patients. 91% of the attending physicians describe the drug as highly effective.
| Original language | English |
|---|---|
| Pages (from-to) | 50-55 |
| Number of pages | 6 |
| Journal | Klinicheskaya Meditsina |
| Volume | 91 |
| Issue number | 6 |
| Publication status | Published - 2013 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
[Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan]. / Nurgozhin, T. S.; Guliaev, A. E.; Ermekbaeva, B. A.; Zhaugasheva, S. K.; Abuova, G. T.; An, É A.
In: Klinicheskaya Meditsina, Vol. 91, No. 6, 2013, p. 50-55.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - [Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan].
AU - Nurgozhin, T. S.
AU - Guliaev, A. E.
AU - Ermekbaeva, B. A.
AU - Zhaugasheva, S. K.
AU - Abuova, G. T.
AU - An, É A.
PY - 2013
Y1 - 2013
N2 - This paper reports results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan. The study included 16312 patients examined in different cities during 2011-2012. It showed that ascoril expectorant (Glenmark) at a standard dose is an effective agent for the treatment of cough in children above 3 years and adults aged up to 78 years with ARVI and acute bronchitis, exacerbation of these conditions or grade I-II chronic obstructire pulmonary disease. Most patients reported good therapeutic effect within 1 day after intake. Ascoril expectorant caused no adverse reactions and was well tolerated by the patients. 91% of the attending physicians describe the drug as highly effective.
AB - This paper reports results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan. The study included 16312 patients examined in different cities during 2011-2012. It showed that ascoril expectorant (Glenmark) at a standard dose is an effective agent for the treatment of cough in children above 3 years and adults aged up to 78 years with ARVI and acute bronchitis, exacerbation of these conditions or grade I-II chronic obstructire pulmonary disease. Most patients reported good therapeutic effect within 1 day after intake. Ascoril expectorant caused no adverse reactions and was well tolerated by the patients. 91% of the attending physicians describe the drug as highly effective.
UR - http://www.scopus.com/inward/record.url?scp=84894475949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894475949&partnerID=8YFLogxK
M3 - Article
C2 - 24417069
AN - SCOPUS:84894475949
VL - 91
SP - 50
EP - 55
JO - Klinicheskaya Meditsina
JF - Klinicheskaya Meditsina
SN - 0023-2149
IS - 6
ER -